Product Description
ATR 1086 is designed to address the underlying genetic driver of disease by reducing PLN expression in cardiac muscle, rather than treating symptoms alone. We believe it has the potential to address a broader population of heart failure and cardiomyopathy patients, particularly those characterized by calcium handling defects and reduced SERCA2a activity. (Sourced from: https://atriumtherapeutics.com/science/)
Mechanisms of Action: PLN Reducer
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Cardiomyopathies
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/23/2026 |
News Article |
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration |